Famotidine ( DrugBank: Famotidine )

5 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
46	Malignant rheumatoid arthritis	2
86	Pulmonary arterial hypertension	1
98	Eosinophilic gastrointestinal disease	1
107	Juvenile idiopathic arthritis	1

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01937078 (ClinicalTrials.gov)	April 2011	26/7/2012	Famotidine for Levodopa-induced Dyskinesia in PD	An 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's Disease	Dyskinesia	Drug: Famotidine	University Health Network, Toronto	NULL	Completed	18 Years	80 Years	Both	7	Phase 2	Canada

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000004271	2009/04/01	27/09/2010	Upper gastrointestinal endoscopic findings in Japanese with rheumatoid arthritis (RA) receiving long-term NSAIDs therapy, and the usefulness of switching to selective COX-2 inhibitor celecoxib	Upper gastrointestinal endoscopic findings in Japanese with rheumatoid arthritis (RA) receiving long-term NSAIDs therapy, and the usefulness of switching to selective COX-2 inhibitor celecoxib - The usefulness of switching to celecoxib in patients with NSAIDs-induced gastrointestinal mucosal injury	Rheumatoid arthritis (RA)NSAIDs-induced gastrointestinal mucosal injury	Japanese rheumatic patients who have been treated with NSAIDs for twelve or more weeks are switched to CEL (400mg/day). Upper GI endoscopy is conducted before and after administration of CEL. Patients with ulcers at the enrollment are switched to CEL (400mg/day) with famotidine (20mg/day) after healing of their pre-existing ulcers following treatment.	Hoshigaoka Koseinenkin Hospital	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	100	Not applicable	Japan
2	NCT00613106 (ClinicalTrials.gov)	September 2007	28/1/2008	Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)	Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)	Osteoarthritis;Rheumatoid Arthritis;Chronic Low Back Pain;Chronic Regional Pain Syndrome;Chronic Soft Tissue Pain	Drug: HZT-501;Drug: Ibuprofen	Horizon Pharma Ireland, Ltd., Dublin Ireland	NULL	Completed	40 Years	81 Years	All	179	Phase 3	United States

86. Pulmonary arterial hypertension

Clinical trials : 1,205 / Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03554291 (ClinicalTrials.gov)	May 1, 2019	31/5/2018	Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension	Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension	Pulmonary Arterial Hypertension;Right Heart Failure	Drug: Famotidine 20 MG;Other: Placebo	University of Washington	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	18 Years	80 Years	All	80	Phase 2	United States

98. Eosinophilic gastrointestinal disease

Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04248712 (ClinicalTrials.gov)	July 10, 2020	28/1/2020	Antihistamines in Eosinophilic Esophagitis	A Phase II, Randomized, Placebo-controlled Study Evaluating the Efficacy of Antihistamines in the Treatment of Eosinophilic Esophagitis (the ATEE Study)	Eosinophilic Esophagitis	Drug: Famotidine;Drug: Loratadine;Drug: Placebo	Mayo Clinic	NULL	Terminated	18 Years	N/A	All	1	Phase 2	United States

107. Juvenile idiopathic arthritis

Clinical trials : 447 / Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01563185 (ClinicalTrials.gov)	April 2012	20/3/2012	Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis	A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis	Juvenile Idiopathic Arthritis	Drug: 800 mg ibuprofen/26.6 mg famotidine	Horizon Pharma Ireland, Ltd., Dublin Ireland	Pediatric Rheumatology Collaborative Study Group	Completed	10 Years	16 Years	All	12	Phase 4	United States